Bibliografía del artículo
1. Zyprexa (olanzapine) tablets and Zyprexa Zydis (olanzapine) orally disintegrating tablets [prescribing information]. Indianapolis, Ind: Eli Lilly and Company, 2004.
2. Abilify (aripiprazole) tablets and oral solution [prescribing information]. Princeton, NJ, and Rockville, Md: Bristol-Myers Squibb Company and Otsuka Amarica Pharmaceutical, Inc, 2005.
3. Department of Health & Human Services. Public Health Service. Food and Drug Administration. Supplemental new drug (Seroquel®) application. Rockville, October 20, 2006.
4. Bret MC, Bret P, Pariente A, Fourier-Réglat A. The use of atypical antipsychotics in French psychiatric hospitals. Pharm World Sci 29(5):551-6, 2007.
5. Woo YS, Bahk WM, Min KJ, et al. Medication prescription pattern for outpatients with bipolar disorder: focusing on atypical antipsychotics. Korean J Psychopharmacol 17(6):538-49, 2006.
6. Cooper WO, Arbogast PG, Hickson GB, Fuchs C, Ray WA. Trends in prescribing of antipsychotic medications for US children. Amb Pediatr 6:79-83, 2006.
7. Gentile S. Atypical antipsychotic for the treatment of bipolar disorder. More shadows than lights. CNS Drugs 21(5):367-87, 2007.
8. Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA 289(4):454-65, 2003.
9. Boyd EA, Cho MK, Bero LA. Financial conflict-of-interest policies in clinical research: issues for clinical investigators. Acad Med 78(8):769-74, 2003.
10. Gentile S. Long term atypical antipsychotics treatment and risk of weight gain. A literature analysis. Drug Saf 29(4):303-19, 2006.
11. Rendell JM, Gijsman HJ, Keck P, Goodwin GM, Geddes JR. Risperidone alone or in combination for acute mania. Cochrane Database Syst Rev (1):CD004043, 2006.
12. Gentile S. Extrapyramidal adverse events associated with atypical antipsychotic treatment of bipolar disorder. J Clin Psychopharmacol 27(1):35-45, 2007.
13. Patel NC, Crismon ML, Pondrom M. Rehospitalization rates of patients with bipolar disorder discharged on a mood stabilizer versus a mood stabilizer plus an atypical or typical antipsychotic. J Behav Health Serv Res 32(4):438-45, 2005.
14. Keck PE Jr, Calabrese JR, McQuade RD, Carson WH, Carlson BX, Rollin LM, for the Aripiprazole Study Group. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 67:626-37, 2006.
15. Keck PE Jr, Calabrese JR, McIntyre RS, McQuade RD, Carson WH, Eudicone JM, et al., for the Aripiprazole Study Group. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry 68:1480-91, 2007.
16. Keck PE, McElroy SL. Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic. Expert Opin Invest Drugs 12:655-62, 2003.
17. Muzina DJ, Momah C, Eudicone JM, et al. Aripiprazole monotherapy in patients with rapid-cycling bipolar I disorder: an analysis from a long-term, double-blind, placebo-controlled study. Int J Clin Pract 62(5):679-87, 2008.
18. Suppes T, Eudicone J, McQuade R, Pikalov III A, Carlson B. Efficacy and safety of aripiprazole in subpopulations of patients with acute or mixed episodes. J Affect Disord 107:145-54, 2008.
19. Sachs G, Sanchez R, Marcus R, Stock E, McQuade R, Carson W, et al., for the Aripiprazole Study Group. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week, placebo-controlled study. J Psychopharm 20:536-46, 2006.
20. Keck Jr. PE, Marcus R, Tourkodimitris S, Ali M, Liebeskind A, Saha S, Ingenito G, and Aripiprazole Study Group. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 160:1651-8, 2003.
21. Zimbroff DL, Marcus RN, Manos G, Stock E, McQuade RD, Auby P, et al. Management of acute agitation in patients with bipolar disorder. Efficacy and safety of intramuscolar aripiprazole. J Clin Psychopharm 27(2):171-6, 2007.
22. Young AH, Oren DA, Lowy A, McQuade RD, Marcus RN, Carson WH, et al. Aripiprazole monotherapy in acute mania: 12-week randomized placebo- and haloperidol-controlled study. Br J Psychiatry 194:40-8, 2009.
23. Thase ME, Jonas A, Khan A, Bowden CL, Wu X, McQuade RD, et al. Aripiprazole monotherapy in non-psychotic bipolar I depression. Results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol 28(1):13-20, 2008.
24. Niufan G, Tohen M, Qiuqing A, Fude Y, Pope E, McElroy H, et al. Olanzapine versus lithium in the acute treatment of bipolar mania: a double-blind, randomized, controlled trial. J Affect Disord 105:101-8, 2008.
25. Tohen M, Vieta E, Goodwin GM, Sun B, Amsterdam JD, Banov M, et al. Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: a randomized, 12-week, double-blind study. J Clin Psychiatry, published online ahead of print: October 7 e1-e14 (pii:ej07m03788), 2008.
26. Moreno RA, Hanna MM, Tavares SM, Wang YP. A double-blind comparison of the effect of the antipsychotics haloperidol and oanzapine on sleep in mania. Braz J Med Biol Res 40:357-66, 2007.
27. Tamayo JM, Mazzotti G, Tohen M, Gattaz WF, Zapata R, Castillo JJ, et al. Outcomes for Latin American versus White patients suffering from acute mania in a randomized, double-blind trial comparing olanzapine and haloperidol. J Clin Psychopharmacol 27(2):126-34, 2007.
28. Tohen M, Bowden CL, Smulevich AB, Bergstrom R, Quinlan T, Osuntokun O, et al. Combination of olanzapine and carbamazepine compared with carbamazepine alone in treating manic episodes. Br J Psychiatry 192:1-9, 2008.
29. Maina G, Albert U, Salvi V, Mancini M, Bogetto F. Valproate or olanzapine add-on to lithium: an 8-week, randomized, open-label study on Italian patients with a manic relapse. J Affect Disord 99:247-51, 2007.
30. Maina G, Albert U, Rosso G, Bogetto F. Olanzapine or lamotrigine addition to lithium in remitted bipolar disorder patients with anxiety disorder comorbidity: a randomized, single-blind, pilot study. J Clin Psychiatry 69:609-16, 2008.
31. Ling H, Ma C, Wang G, Zhu X, Peng M, Gu N. Response and remission rates in Chinese patients with bipolar mania treated for 4 weeks with either quetiapine or lithium: a randomized and double-blind study. Curr Med Res Opin 24(1):1-10, 2008.
32. Severus WE, Kleindienst N, Seemüller F, Frangou S, Möller S, Greil W. What is the optimal serum lithium level in the long-term treatment of bipolar disorder? A review. Bipolar Disord 10(2):231-7, 2008.
33. Langosch JM, Drieling T, Biedermann NC, et al. Efficacy of quetiapine monotherapy in rapid-cycling bipolar disorder in comparison with sodium valproate. J Clin Psychopharm 28(5):555-60, 2008.
34. Endicott J, Rajagopalan K, Minkwitz M, Macfadden W, for the BOLDER study group. A randomized, double-blind, placebo-controlled study of quetiapine in the treatment of bipolar I and II depression: improvement in quality of life. Int J Psychopharmacol 22(1):29-37, 2007.
35. Calabrese JR, Keck PE, Macfadden W, Minkwitz M, Ketter TA, Weisler RH, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 162:1351-60, 2005.
36. Gentile S. A systematic review of quality of life and weight gain related issues in patients treated for severe and persistent mental disorders: focus on aripiprazole. Neuropsychiatr Dis Treat, in press.
37. Suppes T, Hirschfeld RM, Vieta E, Raines S, Paulsson B. Quetiapine for the treatment of bipolar II depression: analysis of data from two randomized, double-blind, placebo-controlled studies. World J Biol Psychiatry 9(3):198-211, 2008.
38. Harvey PD, Hassman H, Mao L, Gharabawi GM, Mahmoud RA, Engelhart LM. Cognitive functioning and acute sedative effects of risperidone and quetiapine in patients with stable bipolar I disorder: a randomised, double-blind, crossover study. J Clin Psychiatry 68:1186-94, 2007.
39. Sheehan DV, McElroy SL, Harnett-Sheehan K, et al. Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety. J Aff Disord, in press.
40. Yatham LN, Fallu A, Binder CE. A 6-month randomized open-label comparison of continuation of oral antipsychotic therapy or switch to long acting injectable risperidone in patients with bipolar disorder. Acta Psychiatr Scand 116(Suppl. 434):30-56, 2007.
41. Mech AV. High-dose ziprasidone monotherapy in bipolar I disorder patients with depressed or mixed episodes. J Clin Psychopharm 28(2):240-1, 2008.
42. Vieta E, Sanchez-Moreno J. Acute and long-term treatment of mania Dialogues Clin Neurosci 10(2):165-79, 2008.
43. Keating GM, Robinson DM. Spotlight on quetiapine in bipolar depression. CNS Drugs 21(8):695-7, 2007.
44. Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 60:1079-1088, 2003.
45. Amsterdam JD, Shults J. Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar I and type II major depression - lack of manic induction. J Affect Dis 87:121-130, 2005.
46. Gentile S. Antipsychotic-associated weight gain. Ann Pharmacother 38(5):903-4, 2004.
47. Soares-Weiser K, Bravo Vergel Y, Beynon S, et al. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of interventions for preventing relapse in people with bipolar disorder. Health Technol Assess 11(39):iii-iv, ix-206, 2007.
48. Led Zeppelin. The House of the Holy: The Song Remains the Same. Available from URL: http://discography.ledzeppelin.com/disc_hoth.html. Accessed: 15 December 2008.